Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ACOU085 for Prevention of Cisplatin-Induced Hearing Loss in Testicular Cancer
NCT06521190Phase 2Recruiting
- Sponsor
- Acousia Therapeutics GmbH
- Start
- Dec 2023
- Primary completion
- Mar 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of bimokalner in cisplatin-induced hearing loss (CIHL) (2 arms), sponsored by Acousia Therapeutics GmbH. Primary endpoint: Pure Tone Audiometry (Air Conduction) at 9 weeks. Started Dec 2023; status: recruiting.
02
Drugs
bimokalner
03
Conditions
cisplatin-induced hearing loss (CIHL)
Beyond the preview
Go deeper on NCT06521190.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06521190.